Literature DB >> 21318097

Establishment and maintenance of HIV latency: model systems and opportunities for intervention.

Matthew D Marsden1, Jerome A Zack.   

Abstract

HAART has succeeded in reducing morbidity and mortality rates in patients infected with HIV. However, a small amount of replication-competent HIV can persist during HAART, allowing the virus to re-emerge if therapy is ceased. One significant source of this persistent virus is a pool of long-lived, latently infected CD4(+) T cells. This article outlines what is known about how this reservoir is established and maintained, and describes the model systems that have provided insights into the molecular mechanisms governing HIV latency. The therapeutic approaches for eliminating latent cells that have been attempted are also discussed, including how improvements in understanding of these persistent HIV reservoirs are being used to develop enhanced methods for their depletion.

Entities:  

Year:  2010        PMID: 21318097      PMCID: PMC3037592          DOI: 10.2217/fvl.09.70

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  134 in total

Review 1.  Immunotoxin treatment of cancer.

Authors:  Ira Pastan; Raffit Hassan; David J FitzGerald; Robert J Kreitman
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

2.  Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.

Authors:  Deirdre D Scripture-Adams; David G Brooks; Yael D Korin; Jerome A Zack
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study.

Authors:  J M Orenstein; M S Meltzer; T Phipps; H E Gendelman
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

Review 4.  Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

5.  Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.

Authors:  Rafael G Amado; Ronald T Mitsuyasu; Joseph D Rosenblatt; Frances K Ngok; Andreas Bakker; Steve Cole; Nathalie Chorn; Lii-Shin Lin; Gregory Bristol; Maureen P Boyd; Janet L MacPherson; Gregory C Fanning; Alison V Todd; Julie A Ely; Jerome A Zack; Geoff P Symonds
Journal:  Hum Gene Ther       Date:  2004-03       Impact factor: 5.695

6.  Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.

Authors:  Leonard C Edelstein; Sophia Micheva-Viteva; Bradley D Phelan; Joseph P Dougherty
Journal:  AIDS Res Hum Retroviruses       Date:  2009-09       Impact factor: 2.205

7.  Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency.

Authors:  Vyjayanthi Krishnan; Steven L Zeichner
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

9.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

Authors:  E Verdin; P Paras; C Van Lint
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

10.  Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons.

Authors:  R V Ramachandran; D A Katzenstein; R Wood; D H Batts; T C Merigan
Journal:  J Infect Dis       Date:  1994-10       Impact factor: 7.759

View more
  13 in total

1.  HIV latency in the humanized BLT mouse.

Authors:  Matthew D Marsden; Michael Kovochich; Nuttee Suree; Saki Shimizu; Roshni Mehta; Ruth Cortado; Gregory Bristol; Dong Sung An; Jerome A Zack
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

3.  Experimental Approaches for Eliminating Latent HIV.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  For Immunopathol Dis Therap       Date:  2015

Review 4.  New generation humanized mice for virus research: comparative aspects and future prospects.

Authors:  Ramesh Akkina
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

5.  Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Feng Fu; Martin A Nowak; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-05       Impact factor: 11.205

Review 6.  Studies of retroviral infection in humanized mice.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Virology       Date:  2015-02-11       Impact factor: 3.616

Review 7.  Humanized Mouse Models for Human Immunodeficiency Virus Infection.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Annu Rev Virol       Date:  2017-07-26       Impact factor: 10.431

8.  HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes.

Authors:  Matthew D Marsden; Bryan P Burke; Jerome A Zack
Journal:  Virology       Date:  2011-07-20       Impact factor: 3.616

9.  Targeting IκB proteins for HIV latency activation: the role of individual IκB and NF-κB proteins.

Authors:  Guerau Fernandez; Thomas D Zaikos; Sohrab Z Khan; Ashley M Jacobi; Mark A Behlke; Steven L Zeichner
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

10.  Stelleralides D-J and Anti-HIV Daphnane Diterpenes from Stellera chamaejasme.

Authors:  Min Yan; Yan Lu; Chin-Ho Chen; Yu Zhao; Kuo-Hsiung Lee; Dao-Feng Chen
Journal:  J Nat Prod       Date:  2015-11-12       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.